<!DOCTYPE html>
<html>
<head>
	<meta charset="utf-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<title>催化剂 | 毕得医药</title>
	<meta name="renderer" content="webkit">
	<meta name="robots" content="index,follow">
	<meta content="telephone=no,email=no" name="format-detection">
	<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no">
	<link rel="shortcut icon" href="https://www.bidepharm.com/static/img/favicon.ico" type="image/x-icon" />
<style type="text/css" media="screen">
*{-webkit-box-sizing: border-box;
-moz-box-sizing: border-box;
box-sizing: border-box;margin:0;padding:0;}
a{text-decoration:none;}
img{max-width:100%;}
html{-webkit-text-size-adjust:none;-ms-text-size-adjust:none;-moz-text-size-adjust:none;text-size-adjust:none}
body{width:100%;font-family:Arial;}
.layout{margin:0 auto;max-width:750px;}
.container p{padding:10px 0;color:#036eb8;font-size:16px;line-height:28px;}
.blue_bg{background:#0374db;color:#fff;text-align:center;}
.blue_bg h1{padding:40px 0;font-size:40px;}
.white_bg h2{margin-top:20px;color:#036eb8;font-size:36px;}
.linghtblue_bg{padding:20px 4%;background:#e6f7fc;}
.img_box{padding:20px 0;}
.img_box{text-align:center;}
.img_box p{margin-top:-10px;padding-top:0;color:#333;text-align:center;font-size:18px;}
.white_bg{padding:20px 4%;background:#fff;}
.box_kuang{border:1px #036eb8 dashed;border-radius:10px;}
.linghtblue_bg .position_box{min-height:200px;}
.position_box{position: relative;min-height:240px;}
.position_box .box_kuang{position:absolute;right:2%;height:150px;}
.position_box .box_kuang img{float:right;max-width:50%}
.position_box .blue_btn{position:absolute;left:2%;top:50px;height:140px;line-height:140px;width:360px;}
.l_position .blue_btn{left:1%;}
.position_box .min_box{width:72%;}
.position_box .max_box{width:85%;}
.position_box .max_box img{max-width:45%}
.blue_btn{z-index:2;display:block;border-radius:10px;background:#0374db;color:#fff;text-align:center;font-weight:700;font-size:44px;}
.padding20 img{padding:10px;}
.span_l,.span_r{float:left;width:50%;text-align:center;}
.position_img{position: absolute;bottom:0;right:0;}
.b_position .box_kuang{bottom:15px;}
.b_position .blue_btn{top:20px;}
sup,sub{display:inline-block;transform:scale(0.9);}

@media only screen and (max-width:680px){
.blue_bg h1{font-size:34px;padding:35px 0;}
.white_bg h2{font-size:32px;}
.linghtblue_bg .position_box{min-height:190px;}
.position_box{min-height:210px;}
.position_box .box_kuang{height:120px;}
.position_box .blue_btn{height:130px;line-height:130px;width:320px;font-size:40px;}
}
@media only screen and (max-width:570px){
.blue_bg h1{font-size:30px;padding:30px 0;}
.white_bg h2{font-size:28px;}
.linghtblue_bg .position_box{min-height:180px;}
.position_box{min-height:190px;}
.position_box .box_kuang{height:110px;}
.position_box .blue_btn{height:120px;line-height:120px;width:280px;font-size:34px;}
.position_box .max_box img{max-width:44%}
}
@media only screen and (max-width:416px){
.container p{line-height:24px;font-size:14px;}
.img_box p {font-size:12px;}
.blue_bg h1{font-size:30px;}
.white_bg h2{font-size:26px;}
.linghtblue_bg .position_box,.position_box{min-height:150px;}
.position_box .box_kuang{height:90px;}
.position_box .blue_btn{height:80px;line-height:80px;width:220px;font-size:30px;}
.img_box{padding:18px 0;}
}
@media only screen and (max-width:376px){
.blue_bg h1{font-size:28px;}
.white_bg h2{font-size:24px;}
.linghtblue_bg .position_box,.position_box{min-height:135px;}
.position_box .box_kuang{height:80px;}
.position_box .blue_btn{height:70px;line-height:70px;width:190px;font-size:24px;}
.position_box .max_box img{max-width:43%}
.img_box{padding:15px 0;}
}
@media only screen and (max-width:321px){
.container p{line-height:22px;padding:8px 0;}
.blue_bg h1{font-size:26px;}
.white_bg h2{font-size:22px;}
.img_box{padding:12px 0;}
.linghtblue_bg .position_box,.position_box{min-height:125px;}
.position_box .box_kuang{height:70px;}
.position_box .blue_btn{height:60px;line-height:60px;width:160px;font-size:22px;}
}
</style>
</head>
<body>
	<!-- catalyst container -->
	<div class="container">
		<div class="blue_bg">
			<div><img src="https://www.bidepharm.com/static/img/wechat/catalyst-01.png" alt=""></div>
			<h1 class="layout">The Applications of Oxazoline-Based Ligands in Asymmetric Catalysis</h1>
		</div>
		<div class="linghtblue_bg">
			<div class="layout">
				<p>
					Asymmetric catalysis with chiral metal catalysts has received considerable attention in recent years, and its contribution to the art of organic synthesis has become of leading importance. The chiral metal catalyst, in general consists of a metal active site coordinating to a chiral organic ligand. Among the various ligands, ligands containing chiral oxazoline rings are one of the most successful and commonly used classes of ligands for asymmetric catalysis due to their ready accessibility, modular nature, and applicability in a wide range of metal-catalyzed transformations with excellent catalytic activity and enantioselectivity.
				</p>
				<p>
					These ligands are derived from readily available chiral amino alcohols in short, high yielding synthetic sequences. The enantiostereocenter resides on the carbon atom, neighboring the coordinating nitrogen of the oxazoline ring which is close to the metal active site, thus having a direct influence on the stereochemical effect of the reaction.
				</p>
				<div class="img_box"><img src="https://www.bidepharm.com/static/img/wechat/catalyst-02.png" alt=""></div>
				<p>
					Since the first report in 1986 of the use of chiral oxazoline-based ligands in asymmetric catalysis, a diverse range of ligands with one, two, or more oxazoline rings incorporating various heteroatoms, additional chiral elements, and specific structural features such as PyOX, PyBOX, BOX, PHOX, TOX have been used with great success in a wide range of asymmetric reactions. Among these ligands, BOX and PHOX are especially useful for a wide range of asymmetric reactions and always be considered as privileged chiral ligands. A wide range of metal-chiral oxazoline catalyzed transformations including oxidations, reductions, cycloadditions, and carbon- carbon bond forming reactions. Some applications of oxazoline-based ligands in asymmetric catalysis are introduced in the following section.
				</p>
			</div>
		</div>
		<div class="white_bg">
			<div class="layout">
				<div class="img_box position_box">
					<div class="box_kuang min_box"><img src="https://www.bidepharm.com/static/img/wechat/catalyst-03.png" alt=""></div>
					<a href="https://www.bidepharm.com/catalyst_pyox.html" target="_blank" class="blue_btn">PyOX</a>
				</div>
				<p>
					Brunner used PyOX as a ligand for asymmetric reactions in 1986, which was the first reported oxazoline-based ligand used in asymmetric reactions. The N, N-bidentate PyOX ligands can be easily modified by changing the substituents on the pyridine and oxazoline rings to finely control the electronic and steric nature of the ligands.
				</p>
				<p>
					In 2012, the Sigman group reported an asymmetric intermolecular Heck-arylation reaction of acyclic alkenyl alcohols using a redox-relay strategy, which delivers β-, γ-, or δ-aryl carbonyl products. The use of an electron-deficient and sterically hindered PyOX ligand, tBu<sup>5</sup>CF<sub>3</sub>Pyox, is crucial for the high yields and enantioselectivities.
				</p>
				<div class="img_box">
					<div class="box_kuang padding20">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-04.png" alt="">
						<p><i>Science</i> <b>2012</b>, <i>338</i>, 1455.</p>
					</div>
				</div>
				<p>
					In 2018, the Liu group established a novel asymmetric 6-endo aminoacetoxylation of unactivated alkenes catalyzed by Pd(OAc)<sub>2</sub> with a new designed PyOX ligand, which yields chiral β-acetoxylated piperidines with excellent chemo-, regio- and enantioselectivities under very mild reaction conditions, the PyOX ligand which has a sterically bulky group at the C-6 position is crucial to enhance the reactivity of the aminoacetoxylation of alkenes.
				</p>
				<div class="img_box">
					<div class="box_kuang padding20">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-05.png" alt="">
						<p><i>J. Am. Chem. Soc.</i> <b>2018</b>, <i>140</i>, 7415.</p>
					</div>
				</div>
				<p>
					In 2019, Zhu et al. reported a terminal-selective, remote asymmetric hydroalkylation of olefins with racemic α-bromo amides. With a chiral nickel-PyOX catalyst, excellent regio- and enantioselectivity were observed with broad substrate scope. The mild, enantioconvergent reaction provides rapid access to a variety of enantioriched α-alkylalkanoic amides in good yields and ee values.
				</p>
				<div class="img_box">
					<div class="box_kuang padding20">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-06.png" alt="">
						<p><i>Angew. Chem., Int. Ed.</i> <b>2019</b>, <i>58</i>, 1754.</p>
					</div>
				</div>
				<div class="img_box">
					<a href="https://www.bidepharm.com/catalyst_pyox.html" target="_blank"><img src="https://www.bidepharm.com/static/img/wechat/catalyst-07.png" alt=""></a>
				</div>
			</div>
		</div>
		<div class="linghtblue_bg">
			<div class="layout">
				<div class="img_box position_box l_position">
					<div class="box_kuang max_box">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-08.png" alt="">
					</div>
					<a href="https://www.bidepharm.com/catalyst_box_pybox.html" target="_blank" class="blue_btn">BOX & PyBOX</a>
				</div>
				<p>
					The basic design of C2-symmetric BOX ligands includes two oxazoline moieties connected by a spacer unit, ligands contain a single carbon spacer unit represent the most prevalent structural motif for the bisoxazolines. Other groups also can be the spacer unit of BOX ligands, among these ligands, the pyridine bisoxazoline(PyBOX) ligands are most common.
				</p>
				<p>
					In 1991 two back-to-back communications appeared in <i>The Journal of the American Chemical Society</i>: one by Evans et al. dealt with the asymmetric cyclopropanation of alkenes and a second  one by Corey et al. that covered enantioselective Diels-Alder reactions. Then the BOX ligands quickly became widely adopted as bidentate ligands for their easy and flexible synthesis and the excellent enantioselectivity in numerous useful reactions catalyzed by metal-BOX complexes.
				</p>
				<div class="img_box">
					<div class="box_kuang padding20">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-09.png" alt="">
						<p>
							<span class="span_l"><i>J. Am. Chem. Soc.</i> <b>1991</b>, <i>113</i>, 726.</span><span class="span_R"><i>J. Am. Chem. Soc.</i> <b> 1991</b>, <i></i>, 728.</span>
						</p>
					</div>
				</div>
				<p>
					In 2016, the Liu group reported a copper-BOX-catalyzed radical relay pathway for enantioselective conversion of benzylic C–H bonds into benzylic nitriles. Hydrogen-atom abstraction affords an achiral benzylic radical that undergoes asymmetric C(sp<sup>3</sup>)–CN bond formation upon reaction with a chiral copper-BOX catalyst. The reactions proceed efficiently at room temperature with the benzylic substrate as limiting reagent, exhibit broad substrate scope with high enantioselectivity (typically 90 to 99% ee), and afford products that are key precursors to important bioactive molecules.
				</p>
				<div class="img_box">
					<div class="box_kuang padding20">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-10.png" alt="">
						<p><i>Science</i> <b>2016</b>, <i>353</i>, 1014.</p>
					</div>
				</div>
				<p>
					In 2019, the Mei group developed a Ni-BOX-catalyzed enantioselective hydroarylation of styrenes with arylboronic acids and realized with good yields and enantioselectivities, it’s an efficient method to access 1,1-diarylalkanes, which are essential structural units in many biologically active compounds, and it could be applied to efficient synthesis of drug molecular (R)-ibuprofen.
				</p>
				<div class="img_box">
					<div class="box_kuang padding20">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-11.png" alt="">
						<p><i>J. Am. Chem. Soc.</i> <b>2019</b>, <i>141</i>, 3395.</p>
					</div>
				</div>
				<p>
					In 2017, Singh et al. reported the use of chiral Sc(III)/Er(III)-PyBOX complexes, which catalyzed an asymmetric vinylogous Mukaiyama-Michael reaction of α,β-unsaturated 2-acyl imidazoles with silyloxyfurans. The reaction is of great importance since many functionalized γlactones can be prepared utilizing this reaction, and these γ-lactones serve as valuable building blocks in many natural products.
				</p>
				<div class="img_box">
					<div class="box_kuang padding20">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-12.png" alt="">
						<p><i>Chem Commun.</i> <b>2017</b>, <i>53</i>, 5143.</p>
					</div>
				</div>
				<p>
					In 2014, Singh and coworkers have successfully developed a method with a high level of enantioselectivity for the synthesis of diversely substituted isoindolinones via an asymmetric alkylation/lactamization cascade in the presence of Cu(I)-diPh-PyBOX catalyst. This methodology was extended to the synthesis of tetrahydroisoquinoline scaffolds.
				</p>
				<div class="img_box">
					<div class="box_kuang padding20">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-13.png" alt="">
						<p><i>Angew. Chem. Int. Ed.</i> <b>2014</b>, <i>53</i>, 10737.</p>
					</div>
				</div>
				<div class="img_box">
					<a href="https://www.bidepharm.com/catalyst_box_pybox.html" target="_blank"><img src="https://www.bidepharm.com/static/img/wechat/catalyst-14.png" alt=""></a>
				</div>
			</div>
		</div>
		<div class="white_bg">
			<div class="layout">
				<div class="img_box position_box b_position">
					<div class="box_kuang min_box"><img class="position_img" src="https://www.bidepharm.com/static/img/wechat/catalyst-15.png" alt=""></div>
					<a href="https://www.bidepharm.com/catalyst_phox.html" target="_blank" class="blue_btn">PHOX</a>
				</div>
				<p>Phosphinooxazolines (PHOX ligands) were introduced in 1993 in three independent publications from the laboratories of Helmchen, Pfaltz, and Williams. Although originally designed as ligands for asymmetric palladium-catalyzed allylic substitutions, they were subsequently applied to many other metal-catalyzed reactions and have established themselves as a widely used class of privileged ligands.</p>
				<p>In 2018, the You group developed a stereodivergent synthesis of tetrahydrofuroindoles through palladium-PHOX-catalyzed asymmetric dearomative formal [3+2] cycloaddition of nitroindoles with epoxybutenes. The polarity of the solvent played a key role in the diastereoselectivity, and the kinetic experiments indicate that the rate-determining step of this reaction is different in different solvents. </p>
				<div class="img_box">
					<div class="box_kuang  padding20">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-16.png" alt="">
						<p><i>Angew. Chem. Int. Ed.</i> <b>2018</b>, <i>57</i>, 2134.</p>
					</div>
				</div>
				<p>Some phosphinooxazoline ligands with a stereoplane were prepared in good to excellent yields with high diastereoselectivity from FeOX, and these ligands have been used for a wide variety of chemical transformations, showing its potential as the need for asymmetric catalysis continues to grow.</p>
				<div class="img_box">
					<div class="box_kuang">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-18.png" alt="">
					</div>
				</div>
				<p>In 2015, the Murakami group developed the combined use of a cationic rhodium(I), a planar chiral phosphinooxazoline ligand(iPr-FOXAP), and norbornene enables the facile preparation of alkenyl pinacolboronates from aliphatic terminal alkenes and HBpin at ambient temperature. The reaction is applied to the one-pot syntheses of aldehydes and homoallylic alcohols from aliphatic terminal alkenes</p>
				<div class="img_box">
					<div class="box_kuang padding20">
						<img src="https://www.bidepharm.com/static/img/wechat/catalyst-19.png" alt="">
						<p><i>Angew. Chem. Int. Ed.</i> <b>2015</b>, <i>54</i>, 12659.</p>
					</div>
				</div>
				<div class="img_box"><a href="https://www.bidepharm.com/catalyst_phox.html" target="_blank"><img src="https://www.bidepharm.com/static/img/wechat/catalyst-20.png" alt=""></a></div>
				<h2>Summary</h2>
				<p>
					The oxazoline-based ligands have played an important role in the development of various enantioselective transformations, and in a broader context have helped to shape the ways that chemists approach asymmetric catalysis. Their use as ligand is seen in enantioselective Mannich reactions, Diels–Alder cycloadditions, free radical reactions, aldol reactions, allylation, crosscoupling reactions and other reactions, various combination of transition metals and oxazolinebased ligands were utilized to achieve these reactions. There is no doubt that these ligands will remain important synthetic targets and will continue to be used as ligands in well-known and new reactions, and these ligands will also undoubtedly play a prominent role in improving the enantioselectivity of existing processes.
				</p>
			</div>
		</div>	
	</div>
</body>
</html>
